Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS episode artwork

EPISODE · Sep 29, 2025 · 4 MIN

Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS

from NeuroFrontiers

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Episode metadata supplied by the publisher feed · Published Sep 29, 2025

Embed this episode

Ready to play

Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS

0:00 4:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of NeuroFrontiers?

This episode is 4 minutes long.

When was this NeuroFrontiers episode published?

This episode was published on September 29, 2025.

Can I download this NeuroFrontiers episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!